Development and Statistical Optimization of Ritonavir Nanosuspension by DOE Approach for Improved Drug Delivery
International Journal of Drug Delivery Technology · 04.06.2026 · 16 (45s)
DOI: 10.25258/ijddt.16.45s.103 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 04.06.2026. Verfasst von Ramanamma Lalam und 1 weiteren Autor:innen.
Abstract (Originalsprache)
The present study aimed to develop and optimize a nanosuspension formulation of ritonavir to enhance its solubility and bioavailability using a Design of Experiments (DOE) approach. Ritonavir, a Biopharmaceutical Classification System (BCS) Class II drug, exhibits poor aqueous solubility, which limits its oral absorption and therapeutic effectiveness. Nanosuspension was prepared using the antisolvent precipitation–ultrasonication method with PVP K30 and Pluronic F-68 as stabilizers. A Central Composite design was employed to evaluate the effect of independent variables, namely PVP K30 concentration (30–56.81 mg), Pluronic F-68 concentration (5–15 mg), and stirring speed (750–1250 rpm), on particle size (Y₁) and percentage drug content (Y₂). The experimental data were analyzed using Design-Expert software, and a quadratic model was found to be significant for both responses (p < 0.05). Among the variables, stirring speed showed the most significant influence, particularly its quadratic effect (p = 0.0030), indicating a strong nonlinear relationship. The optimized formulation was obtained at PVP K30 concentration of 48.14 mg, Pluronic F-68 of 14.72 mg, and stirring speed of 1146.52 rpm, yielding predicted particle size of 98.91 nm and drug content of 98.94%, with a desirability value of 1.000. Validation studies confirmed the reliability of the model, with experimental results closely matching predicted values. In conclusion, the study demonstrated that nanosuspension formulation combined with DOE optimization is an effective strategy to improve the solubility and performance of poorly water-soluble drugs like ritonavir.
Zitieren
APA
Lalam, R., & Kukkar, R. (2026). Development and Statistical Optimization of Ritonavir Nanosuspension by DOE Approach for Improved Drug Delivery. International Journal of Drug Delivery Technology, 16(45s). https://doi.org/10.25258/ijddt.16.45s.103
Vancouver
Lalam R, Kukkar R. Development and Statistical Optimization of Ritonavir Nanosuspension by DOE Approach for Improved Drug Delivery. International Journal of Drug Delivery Technology. 2026;16(45s). doi:10.25258/ijddt.16.45s.103
BibTeX
@article{Lalam2026,
author = {Lalam, Ramanamma and Kukkar, Rajiv},
title = {Development and Statistical Optimization of Ritonavir Nanosuspension by DOE Approach for Improved Drug Delivery},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {45s},
doi = {10.25258/ijddt.16.45s.103}
}
EUVIMED